Acta Cir Bras. 2026 Mar 23;41:e411026. doi: 10.1590/acb411026. eCollection 2026.
ABSTRACT
PURPOSE: To evaluate the efficacy and safety of Ankaferd in comparison with Arista and Surgiflo in a rat zero-ischemia partial nephrectomy model.
METHODS: A total of 28 Wistar albino rats were randomly assigned to four groups: control, Ankaferd, Arista, and Surgiflo. During partial nephrectomy, both the amount of bleeding and bleeding time were recorded. Intra-abdominal adhesions were evaluated on postoperative day 10. Nephrectomy specimens were harvested for histopathological assessment of tubular and glomerular necrosis, as well as for CD142 immunostaining.
RESULTS: Ankaferd demonstrated superior performance in terms of bleeding amount and bleeding time compared with both Arista and Surgiflo, although the differences did not reach statistical significance. Intra-abdominal adhesion scores were higher in the Ankaferd group than in the Arista and Surgiflo groups, with a statistically significant difference compared with the control group (p = 0.01). Histopathological analysis revealed a significantly higher glomerular necrosis score in the Ankaferd group compared with the control group (p = 0.043), while no significant differences were observed for tubular necrosis or CD142 immunohistochemical evaluation among the study groups.
CONCLUSION: Ankaferd achieved more effective and rapid hemostasis than Arista and Surgiflo, but its higher adhesion scores limit its reliability for intra-abdominal use.
PMID:41880472 | DOI:10.1590/acb411026
